Nephrocare Health Services Limited
₹615.95-₹14.40 (-2.3%)
Last close · Data as of Oct 30, 2026
- Market cap
- ₹4,815 Cr
- P/E
- 141.0x
- EV / EBITDA
- 82.3x
- Revenue
- ₹544 Cr
- Net margin
- 0.9%
- ROCE
- 8.9%
Price chart
Technical chartScreen technicals →+30.6% over the last year
Daily closes.
Go deeper
Technical chart: candles, 9 moving averages, RSI, MACD and drawing tools
Performance
Price change over each period, before dividends.
- 1M
- -6.7%
- 3M
- -9.8%
- 6M
- +16.3%
- 1Y
- +30.6%
- 5Y
- +36.9%
52-week range
Day change -₹14.40 (-2.3%) from ₹630 to ₹616 · Last close Oct 30, 2026
AI Summary
Indian StockStrengths1
- Revenue grew 24.8% YoY
Concerns1
- Low return on equity of 1.0%
Rule-based from financial data. Not advice.
About the company
Nephrocare Health Services Limited operates a chain of kidney care clinics that provides dialysis healthcare services with dialysis centres in India, Uzbekistan, Nepal, Kingdom of Saudi Arabia, and the Philippines. It provides In-clinic dialysis, dialysis on call, home hemodialysis, holiday dialysis, and dialysis on wheels services. Nephrocare Health Services Limited was incorporated in 2009 and is based in Hyderabad, India.
- Sector
- Healthcare
- Shares outstanding
- 10.0 Cr shares
- ISIN
- INE428V01029
- BSE code
- 544647
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- ₹4,815 Cr
- P/E
- 141.0x
- EV / EBITDA
- 82.3x
- EV / Sales
- 11.3x
- P/S
- 11.0x
- Earnings yield
- 0.7%
- 52-week high
- ₹766.55
- 52-week low
- ₹449.85
Profitability
- Operating margin
- 11.9%
- Net margin
- 0.9%
- EBITDA margin
- 13.8%
- ROE
- 1.0%
- ROCE
- 8.9%
- ROA
- 0.6%
- Dividend payout
- 0.0%
- Tax rate
- -1668.0%
Growth
- RevenueLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹544 Cr
- Revenue growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 24.8%
- EBITDALatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹60.0 Cr
- EBITDA growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 39.5%
- Net profit growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 750.0%
- Cash from operationsLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- ₹57.0 Cr
- CFO growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 418.2%
- Free cash flowLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- -₹1.00 Cr
- Asset growth, 1YLatest stored company figure. It is not dated and can be a year behind the FY2025 statements; the Growth card lists each year.
- 2.8%
Solvency and efficiency
- Current ratio
- 5.44
- Debt / Equity
- 0.45
- Debt / Assets
- 0.27
- Debt / EBITDA
- 3.03
- Interest coverage
- 3.06
- Financial leverage
- 1.66
- CFO / Net profit
- 14.25
- Cash / Market cap
- 6.2%
- Cash per share
- ₹29.61
- Asset turnover
- 0.66
- Fixed asset turnover
- 1.99
- Capital intensity
- 0.50
- Debtor days
- 116 days
- Inventory turnover
- 7.16
- Cash conversion cycle
- 59 days
Where the revenue went
Some FY2025 lines are not reported, so the ones that are appear as a table.
| Line | FY2025 |
|---|---|
| Sales | ₹544 Cr |
| Expenses | ₹449 Cr |
| Operating profit | ₹95 Cr |
| Other income | ₹16 Cr |
| Interest | ₹14 Cr |
| Depreciation | ₹51 Cr |
| Profit before tax | ₹45 Cr |
| Tax and other | ₹11 Cr |
| Net profit | ₹34 Cr |
Revenue and net profit
Revenue grew 24.8% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2021 | ₹284 Cr | ₹1 Cr |
| FY2022 | ₹317 Cr | -₹22 Cr |
| FY2023 | ₹386 Cr | -₹15 Cr |
| FY2024 | ₹436 Cr | ₹4 Cr |
| FY2025 | ₹544 Cr | ₹34 Cr |
Cash flows
FY2025: ₹80.0 Cr from operations, -₹24.0 Cr free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2021 | ₹33 Cr | -₹31 Cr |
| FY2022 | ₹12 Cr | -₹155 Cr |
| FY2023 | ₹11 Cr | -₹64 Cr |
| FY2024 | ₹57 Cr | ₹34 Cr |
| FY2025 | ₹80 Cr | -₹24 Cr |
Growth
Latest fiscal year FY2025 (ending March): each figure with its change over the year before.
- Revenue
- ₹544 Cr+24.8%1Y
- Net profit
- ₹34 Cr+750.0%1Y
- Cash from operations
- ₹80 Cr+40.4%1Y
- Free cash flow
- -₹24 Cr-170.6%1Y
| Year | Revenue | Operating income | EBITDA | Net profit | CFO | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | ₹544 Cr | ₹95 Cr | — | ₹34 Cr | ₹80 Cr | -₹24 Cr | 6.3% | +24.8% | +750.0% |
Monthly returns
Month-by-month returns of NEPHROPLUS across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Liabilities and equity | ₹757 Cr |
| Equity capital | ₹2 Cr |
| Reserves | ₹537 Cr |
| Borrowings | ₹127 Cr |
| Other liabilities | ₹92 Cr |
| Assets | ₹757 Cr |
| Fixed assets | ₹234 Cr |
| Capital work in progress | ₹4 Cr |
| Investments | ₹212 Cr |
| Other assets | ₹306 Cr |
Market cap against peers
8 peers: same sector group, nearest by size.
P/E against peers
NEPHROPLUS trades at 141.0x earnings against a peer median of 52.6x (a 168% premium).
Not shown (no positive earnings and no EV / Sales): Sun Pharma Advanced Research Company Ltd., Dishman Carbogen Amcis Limited.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| Nephrocare Health Services LimitedNEPHROPLUSthis companyP/E ↑ premium | ₹4,815 Cr | 141.0x | — | 1.0% | 82.3x |
| Supriya Lifescience LimitedSUPRIYA | ₹5,938 Cr | 32.6x | 5.5x | 14.6% | 31.4x |
| Shilpa Medicare Ltd.SHILPAMED | ₹5,771 Cr | 52.6x | 2.2x | 1.3% | 53.7x |
| Entero Healthcare Solutions LimitedENTERO | ₹5,316 Cr | 124.0x | 3.2x | 2.3% | 89.2x |
| Sun Pharma Advanced Research Company Ltd.SPARC | ₹4,415 Cr | — | -12.6x | -312.9% | -11.7x |
| Dishman Carbogen Amcis LimitedDCAL | ₹4,132 Cr | — | 1.0x | -1.9% | 67.5x |
| Artemis Medicare Services LimitedARTEMISMED | ₹4,059 Cr | 42.6x | 4.0x | 10.8% | 32.0x |
| Gujarat Themis Biosyn Ltd.GUJTHEM | ₹4,008 Cr | 83.0x | 15.1x | 29.4% | 48.1x |
| INNOVA CAPTAB LIMITEDINNOVACAP | ₹3,945 Cr | 51.8x | 4.6x | 9.4% | 34.2x |
| Peer median | — | 52.6x | 5.9x | 12.1% | 38.3x |
Year-to-date ROI
NEPHROPLUS since 1 January, against earlier years.
Historical volatility
NEPHROPLUS's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, in ₹ crore, grouped into plain-language lines.
Figures in ₹ crore as reported, fiscal years ending March, newest first; the trailing twelve months (TTM) last.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2021 | 13.0% |
| FY2022 | 6.0% |
| FY2023 | 10.0% |
| FY2024 | 12.0% |
| FY2025 | 17.0% |
| Line | FY2025 |
|---|---|
| RevenueSales | ₹544 Cr |
| Costs | |
| Interest | ₹14 Cr |
| Expenses | ₹449 Cr |
| Operating profitOperating Profit | ₹95 Cr |
| Other income and charges | |
| Profit before tax | ₹45 Cr |
| Tax | |
| Net profitNet Profit | ₹34 Cr |
| Per share |
| Line | FY2025 |
|---|---|
| Liabilities and equityTotal Liabilities | ₹757 Cr |
| Equity capitalEquity Capital | ₹2 Cr |
| Reserves | ₹537 Cr |
| Borrowings | ₹127 Cr |
| Other liabilitiesOther Liabilities | ₹92 Cr |
| AssetsTotal Assets | ₹757 Cr |
| Fixed assetsFixed Assets | ₹234 Cr |
| Capital work in progressCWIP | ₹4 Cr |
| Investments | ₹212 Cr |
| Other assetsOther Assets | ₹306 Cr |
| Line | FY2025 |
|---|---|
| Operating cash flowCash from Operating Activity | ₹80 Cr |
| Investing cash flowCash from Investing Activity | -₹104 Cr |
| Financing cash flowCash from Financing Activity | ₹26 Cr |
| Change in cashNet Cash Flow | ₹2 Cr |
Learn while you research
Academy chapters picked for Nephrocare Health Services Limited and the metrics on this page.
- 01 Taxes on Investments (India)LTCG, STCG, dividend tax, what every Indian investor needs.6 min read
- 02 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 03 Valuation Multiples ExplainedThis stock trades at a P/E of 141.0, learn when high multiples are justified.6 min read
- 04 Growth Investing25% revenue growth is in the top tier, learn how to value growth.7 min read
- 05 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 06 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read